NasdaqGS:UTHRBiotechs
Is It Too Late To Consider United Therapeutics (UTHR) After Its 94% One Year Surge?
Investors may be wondering whether United Therapeutics at around US$596.76 is still offering value after a strong run, or if the easy gains are already behind it.
The stock has recent returns of 4.5% over 7 days, 6.6% over 30 days, 20.1% year to date, 94.4% over 1 year and 181.2% over 3 years. This puts valuation questions front and center for anyone considering it today.
Recent coverage has focused on United Therapeutics as a high growth biotech with a strong pipeline and regulatory...